A Randomized, Double-blind, 2-way Crossover, Multicenter Study to Evaluate the Safety of Test Propellant HFA-152a and Reference Propellant HFA-134a When Administered Via Metered Dose Inhalers
This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).
• Participant must be aged greater than equal to (\>=)18 years at the time of signing the informed consent.
• Participants with asthma for \>= 6 months, defined as:
⁃ Documented history of asthma, as defined by Global Initiative for Asthma (GINA)
• Receiving one of following asthma treatments for at least 12 weeks prior to the screening visit and which is anticipated to remain stable for the duration of the study:
• Short-Acting beta2-Adrenoreceptor Agonists (SABA) as needed (prn) only
• Inhaled corticosteroid (ICS)/SABA prn only
• SABA prn plus ICS prn
• SABA prn plus ICS maintenance
• ICS/SABA prn plus ICS maintenance
• SABA prn plus ICS/ Long-acting beta agonist (LABA) maintenance
• ICS/SABA prn plus ICS/LABA maintenance
• SABA prn plus ICS/ Long-acting muscarinic antagonist (LAMA)/LABA maintenance (open or closed triple therapy)
• ICS/Formoterol combination therapy as reliever therapy
• ICS/Formoterol combination therapy as maintenance therapy plus ICS/Formoterol combination as reliever therapy.
• Leukotriene receptor antagonist (LTRA) as add-on any of the above is permitted
• Xanthines as add-on to any of the above permitted
• Biological therapies indicated for the treatment of asthma as add-on to any of the above are permitted (for example, but not limited to, mepolizumab, dupilumab, tezepelumab).
• Participants with severity of disease:
• Baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1) \>=50 percent (%) of predicted at screening.
• Asthma Control Status
• Asthma Control Questionnaire (ACQ)-6 score less than (\<) 1.5 at screening (and randomization).
• Asthma that has remained stable with no severe exacerbations within the last 3 months.
• Participants who are current non-smokers, who have not used any inhaled tobacco or vaping products within 12 months of the start of the study, and with a total pack year history of less than equal to (\<=)10 pack. The use of inhaled marijuana, even with a valid prescription, is prohibited within 12 months prior to study start.
• Participants who demonstrate ability to use pressurized MDI device in a satisfactory and repeatable manner, as judged visually by the investigator or designee.
• Male and female participants are eligible.
‣ A female participant is eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:
• Is a Participant of nonchildbearing potential (PONCBP) or
• Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of \<1%, 30 days prior to and during the study intervention period and for at least 24 hours after the last dose of study intervention. - A POCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention in each Treatment Period.
⁃ Adults capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF).